Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Liquid vs Lyophilized MenC-CRM in Toddlers
NCT01434680Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Nov 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group c conjugate vaccine in meningococcal meningitis and meningococcal disease (3 arms), sponsored by Novartis. Primary endpoint: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C at Day 29. Started Sep 2011; status: completed.
02
Drugs
meningococcal group c conjugate vaccine
03
Conditions
meningococcal meningitismeningococcal disease
Beyond the preview
Go deeper on NCT01434680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01434680.